Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Mary Bridge Children's Hospital and Health Center
mi
from
Tacoma, WA
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Mary Bridge Children's Hospital and Health Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Madigan Army Medical Center
mi
from
Tacoma, WA
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Madigan Army Medical Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
West Virginia University Charleston
mi
from
Charleston, WV
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
West Virginia University Charleston
mi
from
Charleston, WV
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Marshfield Clinic
mi
from
Marshfield, WI
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Sydney Children's Hospital
mi
from
Randwick,
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Sydney Children's Hospital
mi
from
Randwick,
Click here to add this to my saved trials
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
A Pilot Study of Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
Status: Enrolling
Updated:  10/20/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
A Pilot Study of Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/20/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
A Pilot Study of Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
Status: Enrolling
Updated:  10/20/2015
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
A Pilot Study of Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/20/2015
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
A Pilot Study of Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
Status: Enrolling
Updated:  10/20/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
A Pilot Study of Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/20/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
A Pilot Study of Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
Status: Enrolling
Updated:  10/20/2015
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
A Pilot Study of Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/20/2015
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
A Pilot Study of Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
Status: Enrolling
Updated:  10/20/2015
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
A Pilot Study of Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/20/2015
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy
Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS)
Status: Enrolling
Updated:  10/20/2015
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy
Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS)
Status: Enrolling
Updated: 10/20/2015
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients: A Randomized Phase III Non-inferiority Trial
Status: Enrolling
Updated:  10/20/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients: A Randomized Phase III Non-inferiority Trial
Status: Enrolling
Updated: 10/20/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients: A Randomized Phase III Non-inferiority Trial
Status: Enrolling
Updated:  10/20/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients: A Randomized Phase III Non-inferiority Trial
Status: Enrolling
Updated: 10/20/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
Pilot Study of Fosaprepitant (MK-0517) for Breakthrough Chemotherapy Induced Nausea and Vomiting
Status: Enrolling
Updated:  10/20/2015
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
Pilot Study of Fosaprepitant (MK-0517) for Breakthrough Chemotherapy Induced Nausea and Vomiting
Status: Enrolling
Updated: 10/20/2015
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Daptomycin in Treating Neutropenia and Fever in Patients With Cancer
Phase II Open Label Pilot Trial of Empiric Daptomycin Treatment for Oncology Patients With Neutropenic Fever
Status: Enrolling
Updated:  10/20/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Daptomycin in Treating Neutropenia and Fever in Patients With Cancer
Phase II Open Label Pilot Trial of Empiric Daptomycin Treatment for Oncology Patients With Neutropenic Fever
Status: Enrolling
Updated: 10/20/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
A Phase II Open-Label Study of Sorafenib Plus Fulvestrant as Salvage Therapy for Hormone Receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment
Status: Enrolling
Updated:  10/20/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
A Phase II Open-Label Study of Sorafenib Plus Fulvestrant as Salvage Therapy for Hormone Receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment
Status: Enrolling
Updated: 10/20/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma
Status: Enrolling
Updated:  10/21/2015
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma
Status: Enrolling
Updated: 10/21/2015
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy
Chemotherapy and Anti-angiogenic Agents- Induced Thrombosis in Cancer.
Status: Enrolling
Updated:  10/21/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy
Chemotherapy and Anti-angiogenic Agents- Induced Thrombosis in Cancer.
Status: Enrolling
Updated: 10/21/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy
Compassionate Use of Aldoxorubicin in Sarcoma Patients Who Have Failed Prior Chemotherapy
Status: Enrolling
Updated:  10/21/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy
Compassionate Use of Aldoxorubicin in Sarcoma Patients Who Have Failed Prior Chemotherapy
Status: Enrolling
Updated: 10/21/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Pilot Study Of Valganciclovir In Patients With Classic, Non-HIV-Associated Kaposi's Sarcoma
Status: Enrolling
Updated:  10/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Pilot Study Of Valganciclovir In Patients With Classic, Non-HIV-Associated Kaposi's Sarcoma
Status: Enrolling
Updated: 10/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Pilot Study Of Valganciclovir In Patients With Classic, Non-HIV-Associated Kaposi's Sarcoma
Status: Enrolling
Updated:  10/21/2015
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Pilot Study Of Valganciclovir In Patients With Classic, Non-HIV-Associated Kaposi's Sarcoma
Status: Enrolling
Updated: 10/21/2015
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Pilot Study Of Valganciclovir In Patients With Classic, Non-HIV-Associated Kaposi's Sarcoma
Status: Enrolling
Updated:  10/21/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Pilot Study Of Valganciclovir In Patients With Classic, Non-HIV-Associated Kaposi's Sarcoma
Status: Enrolling
Updated: 10/21/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Ovarian Tissue Cryopreservation in Females Undergoing Procedures That Will Potentially Lead To Loss of Ovarian Function
Ovarian Tissue Cryopreservation As A Means Of Preserving Ovarian Function in Females Undergoing Therapeutic Procedures That Will Potentially Lead To The Irreversible Loss of Ovarian Function
Status: Enrolling
Updated:  10/21/2015
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Ovarian Tissue Cryopreservation in Females Undergoing Procedures That Will Potentially Lead To Loss of Ovarian Function
Ovarian Tissue Cryopreservation As A Means Of Preserving Ovarian Function in Females Undergoing Therapeutic Procedures That Will Potentially Lead To The Irreversible Loss of Ovarian Function
Status: Enrolling
Updated: 10/21/2015
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Ovarian Tissue Cryopreservation in Females Undergoing Procedures That Will Potentially Lead To Loss of Ovarian Function
Ovarian Tissue Cryopreservation As A Means Of Preserving Ovarian Function in Females Undergoing Therapeutic Procedures That Will Potentially Lead To The Irreversible Loss of Ovarian Function
Status: Enrolling
Updated:  10/21/2015
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Ovarian Tissue Cryopreservation in Females Undergoing Procedures That Will Potentially Lead To Loss of Ovarian Function
Ovarian Tissue Cryopreservation As A Means Of Preserving Ovarian Function in Females Undergoing Therapeutic Procedures That Will Potentially Lead To The Irreversible Loss of Ovarian Function
Status: Enrolling
Updated: 10/21/2015
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
A Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination With Isotretinoin (13-cis Retinoic Acid, 13-CRA) in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/22/2015
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
A Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination With Isotretinoin (13-cis Retinoic Acid, 13-CRA) in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/22/2015
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
A Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination With Isotretinoin (13-cis Retinoic Acid, 13-CRA) in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  10/22/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
A Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination With Isotretinoin (13-cis Retinoic Acid, 13-CRA) in the Treatment of Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 10/22/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
Feasibility of Dose Titrating Paricalcitol (Zemplar) in Women Receiving Taxanes or Ixabepilone for Metastatic Breast Cancer
Status: Enrolling
Updated:  10/22/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
Feasibility of Dose Titrating Paricalcitol (Zemplar) in Women Receiving Taxanes or Ixabepilone for Metastatic Breast Cancer
Status: Enrolling
Updated: 10/22/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Fayetteville, AR
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Athens, GA
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Athens, GA
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Kansas City, MO
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Fargo, ND
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Birmingham, AL
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Tucson, AZ
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Duarte, CA
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
La Jolla, CA
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
New Haven, CT
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Hollywood, FL
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Hollywood, FL
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Tampa, FL
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
West Palm Beach, FL
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Marietta, GA
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Thomasville, GA
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Thomasville, GA
Click here to add this to my saved trials
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated:  10/22/2015
Clinical Research Facility
mi
from
Chicago, IL
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
Status: Enrolling
Updated: 10/22/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials